INTRODUCTION
(1) Urinary Pregnanediol
In the women of post-ovulatory phase, who were administered with 2 mg of ergocornine, and five pregnant women, collection of 24 hours specimens of urine was done before and after administration for the estimation of pregnane diol. In ten women given 10 mg and other five treated with dosage of 20 mg, urine specimens were collected on 3 different occasions for 24 hours each time;
i.e.; 1) before the administration, 2) 6th day after the beginning and 3) 9th day after the beginning of administration.
Collection of 24 hours urine also was done in 5 women, who received 10 mg of the drug, for seven consecutive days between the day before and after administration. (1) Urinary Pregnanediol Table  1 Estimations of Pregnanediol in Urine of Women Treated with 2 mg of Ergocornine Metanesulphonate Table 2 Urinary Excretion of Pregnanediol in Pregnant Women Table 3 summarizes the results in 10 women given 10 mg and in five treated with 20 mg of the drug. Subjects, who showed lowered level of excretion after administration, were 7 out of 10 with 10 mg group and 3 out of five with 20 mg group respectively. In this group of cases, however, there was no case that showed lowered level less than 1.0 mg per day, such as women of luteal insufficiency usually did 26, 27
The results of estimation in urines, which were collected for seven con secutive days, are shown in Fig. 1 (2) Other Steroids in Urine Table 6 Classification of B.B.T. Pattern in Cycles during Ergocornine and Previous Cycles Table 7 Dating Diagnosis of Endometriurn in Women Treated with 10 mg and 20 mg of Ergocornine Fig. 2 Table 8 Vaginal Smear Index in 20 Women on the 9th and 14th Day of Menstrual Cycle 9th day and the 14th day of menstrual cycle, did not show any significant difference between cycles during ergocornine administration and previous cycles. Table 9 Recovery Rate of Radioactivity as Pregnanediol and Pregnanetriol in Urine after Injection of Pregnenolone-C14 Recovery of injected radioactive material is presented in Table 9 and Fig. 4 . It appears from the data of Table 9 , that nearly 80 per cent of recovered parts as pregnanediol and pregnanetriol was excreted into urine within 48 hours.
MATERIAL AND METHODS:
This investigation was carried out on eight women, who were admitted to the hospital and were at some day between 3 and 10 day of high tem perature phase. These subjects were divided into two groups. For were treated orally with 8 mg of ergocornine for two days and another four were chosen for control. Two micro-curies of pregnenolone labelled with C14 were injected subcutaneously on some day between 3 and 10 day during high tem perature phase. Then, 24 hours' urine, specimens were collected during next two days. Estimation of urinary excretion of pregnanediol and its radioactivity was carried out in each of these samples.
The pregnenolone-4-C14 used, batch number 79-139-NEC-375, had a specific activity of 45.8 me per millimole. Papaer chromatography of the preparation revealed only one sopt, containing at least 95 per cent of the radioactivity.
Stock soultions were evaporated at room temperature and solutions for injection were prepared by being resolved into 2 ml of sterile-olive oil solution.
Out of the benzen extracts (20 ml) after completion of the second column chromatography in the Klopper-Kanbegawa's quantitative procedure, 1/20, 1/50, 1/100 aliquots were taken, transferred to alminium planchettes and dried at room temperature.
The radioactivity of these samples was measured by a windowless gas flow radiation counter (ALOKA TDC 2-type). The results of this investigation are summarized in Table 10 and Fig. 5 .
In women given ergocornine, mean value of urinary pregnanediol excretion for the first and second day was 0.85 and 1.09 mg per day, respectively, thus showing the lowered level of pregnanediol presumably by the effect of ergocornine ad ministration. Whereas, in the control group, the average for the first and the (1) Seven out of ten women, who received 2 mg, showed a fall in preg nanediol excretion after ergocornine administration, while the remaining 3 did
show slight rise in its value. Seven out of 10 subjects treated with this ergot alkaloid of 10 mg revealed a drop on pregnanediol level. Three out of 5 cases who received 20 mg of this agent disclosed the similar result. The mean value of urinary pregnanediol excretion in women given 8 mg (0.97 mg/day) was de finitely lower than that of the control group (1.64 mg/day). These results do not support Shelesnyak's hypothesis, that the effect of ergocornine might be due to a blocking of the enzyme 3 p-hydroxysteroid dehydrogenase which are essential for the endogenous production of progesterone. 
The mean value of urinary pregnanediol level in the group treated with ergocornine was found to be lower, as compared with that of the control.
There was no distinct difference, on the contrary, in the count per minute of C14
as pregnanediol between two groups.
The effects of this drug on the B.B.T. curve, uterine endometrium, the amount of cervical mucous and the vaginal smear index were also studied in women of normal mestrual cycles.
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